AlzeCure Pharma AB (publ)

OM:ALZCUR Stock Report

Market Cap: SEK 114.8m

AlzeCure Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ALZCUR?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders3,967,9344.49%
Institutions7,824,6538.86%
Private Companies20,243,21022.9%
General Public56,259,40363.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.2%.

Top Shareholders

Top 19 shareholders own 36.97% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.91%
Bwg Invest S.à R.L.
8,747,295SEK 11.4m0%no data
4.98%
FV Group AB
4,400,000SEK 5.7m0%no data
4.98%
Sjuenda Holding AB
4,400,000SEK 5.7m0%no data
2.76%
Avanza Fonder AB
2,436,510SEK 3.2m0%no data
2.59%
Skandinaviska Enskilda Banken AB, Private Banking, Investment Banking, and Insurance Arm
2,286,666SEK 3.0m0%no data
2.1%
Futur Pension Försäkringsaktiebolag, Asset Management Arm
1,856,230SEK 2.4m0%0.08%
2.09%
Nordnet AB (publ), Asset Management Arm
1,847,903SEK 2.4m0%0.04%
1.94%
Alzecure Discovery AB
1,710,000SEK 2.2m0%no data
1.7%
Thomas Pollare
1,501,293SEK 2.0m0%no data
1.12%
Acturum Life AB
985,915SEK 1.3m0%no data
1.03%
Pontus Forsell
907,477SEK 1.2m0%no data
0.99%
Johan Sandin
875,834SEK 1.1m0%no data
0.46%
Martin Jönsson
409,466SEK 532.3k0%no data
0.14%
Birgitta Lundvik
122,500SEK 159.3k0%no data
0.084%
Marta Storck
74,166SEK 96.4k0%no data
0.056%
Ragnar Linder
49,698SEK 64.6k0%no data
0.028%
Janet Hoogstraate
25,000SEK 32.5k0%no data
0.0066%
FCG Fonder AB
5,797SEK 7.5k0%no data
0.0028%
Eva Lilienberg
2,500SEK 3.2k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/12 13:52
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AlzeCure Pharma AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonas PeciulisEdison Investment Research
Fredrik ThorRedeye
Felicia RittemarVator Securities AB